CRYOPORT, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
CRYOPORT, INC. (CYRX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $6.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.71M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.67M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.22M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $6.36M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $6.71M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $9.67M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $3.22M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $6.36M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $9.45M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $3.90M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $8.24M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $16.81M 10-Q · filed 2024-05-08 |
| 2023-09-30 | $3.91M 10-Q · filed 2023-11-09 |
| 2022-09-30 | $3.74M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $7.46M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $11.26M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $3.70M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $7.44M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $10.72M 10-Q · filed 2021-05-06 |
| 2020-09-30 | $134.25K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $268.50K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $402.75K 10-Q · filed 2020-05-08 |
| 2019-09-30 | $134.25K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $268.50K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |